The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study.
 
Jian Zhang
No Relationships to Disclose
 
Rujiao Liu
No Relationships to Disclose
 
Shuiping Gao
No Relationships to Disclose
 
Wenyan Chen
No Relationships to Disclose
 
Xinghua Han
No Relationships to Disclose
 
Yanjie Ma
Employment - Betta Pharmaceuticals
Honoraria - Betta Pharmaceuticals
 
Lieming Ding
Employment - Betta Pharmaceuticals; Betta Pharmaceuticals (I)
Leadership - Betta Pharmaceuticals; Betta Pharmaceuticals (I)
Stock and Other Ownership Interests - Betta Pharmaceuticals; Betta Pharmaceuticals (I)
Honoraria - Betta Pharmaceuticals; Betta Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - Betta Pharmaceuticals
 
Jiabing Wang
Employment - Betta Pharmaceuticals
Leadership - Betta Pharmaceuticals
Stock and Other Ownership Interests - Betta Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Betta Pharmaceuticals
Travel, Accommodations, Expenses - Betta Pharmaceuticals
 
Hong Lan
Employment - Betta Pharmaceuticals
Leadership - Betta Pharmaceuticals
Stock and Other Ownership Interests - Betta Pharmaceuticals
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca